485 related articles for article (PubMed ID: 30366604)
1. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
2. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
[TBL] [Abstract][Full Text] [Related]
3. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
4. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
[TBL] [Abstract][Full Text] [Related]
5. Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary.
Korda D; Doros A; Piros L; Gerlei Z; Haboub-Sandil A; Mándli T; Fazakas J; Deák ÁP; Máthé Z
Transplant Proc; 2019 May; 51(4):1251-1253. PubMed ID: 31101208
[TBL] [Abstract][Full Text] [Related]
6. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
7. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
[TBL] [Abstract][Full Text] [Related]
8. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
9. Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor.
Shen YH; Chen S; Zhang WT; Ji Y; Yu L; Sun HC; Qiu SJ; Ren N; Zhou J
J Cancer Res Ther; 2014 Dec; 10 Suppl():276-80. PubMed ID: 25693935
[TBL] [Abstract][Full Text] [Related]
10. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.
Partelli S; Maurizi A; Tamburrino D; Baldoni A; Polenta V; Crippa S; Falconi M
Eur J Endocrinol; 2014 Oct; 171(4):R153-62. PubMed ID: 24920289
[TBL] [Abstract][Full Text] [Related]
11. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
12. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
13. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
14. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.
Hüttner FJ; Schneider L; Tarantino I; Warschkow R; Schmied BM; Hackert T; Diener MK; Büchler MW; Ulrich A
Langenbecks Arch Surg; 2015 Aug; 400(6):715-23. PubMed ID: 26198970
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
16. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
18. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
[TBL] [Abstract][Full Text] [Related]
19. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic neuroendocrine tumour arising in Meckel's diverticulum coexisting with colon adenocarcinoma.
Katalinic D; Santek F; Juretic A; Skegro D; Plestina S
World J Surg Oncol; 2014 Nov; 12():358. PubMed ID: 25427657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
